KDX1381

KDX1381 is a bivalent CK2α inhibitor (IC50: 17 nM, KD: 54 nM) . KDX1381 has antitumor activity in mouse 786-O and A375 tumor xenograft models. KDX1381 combined with VEGFR inhibitors or DNA damaging agents enhances antitumor efficacy in mouse hepatocellular carcinoma and glioma models[1].

Product Specifications

CAS Number

[2757728-47-3]

UNSPSC

12352005

Target

Casein Kinase

Related Pathways

Cell Cycle/DNA Damage; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

FC1=CC=CC(O)=C1C2=CC=C(S(NCCN3CCC(CN4C=C(C5=C(C(C)=O)NC6=C5C=C(F)C=C6)N=N4)CC3)(=O)=O)C=C2

Molecular Formula

C32H32F2N6O4S

Molecular Weight

634.70

References & Citations

[1]Marlhoux L, et al. Discovery of KDX1381, a Bivalent CK2α Inhibitor for the Treatment of Solid Tumors as a Single Agent or in Combination. J Med Chem. 2025 Jun 26;68 (12) :12819-12844.